Table 1 Urinary podocalyxin concentration in glomerulonephritis
IndicationStudyuPODXL Concentration
Diabetic nephropathy (DN)Hara et al. [19]27.3 ± 3.3 ng/μmol Cr (cf. 7.1± 0.5 in healthy controls)
Shoji et al. [21]58.9 mg/g Cr in diabetic patients with macroalbuminuria (2-fold more than patients with normoalbuminuria)
Focal segmental glomerulosclerosis (FSGS)Hara et al. [19]37.1 ± 11.7 ng/μmol Cr (cf. 7.1± 0.5 in healthy controls)
Zhu et al. [20]10.6-fold increase in uPODXL/uAQP2 concentration relative to healthy controls
Membranous nephropathy (MN)Hara et al. [19]71.4 ± 3.8 ng /μmol Cr (cf. 7.1± 0.5 in healthy controls)
Zhu et al. [20]4.4-fold increase in uPODXL/uAQP2 concentration relative to healthy controls
Lupus nephritis (LN)Hara et al. [19]44.3 ± 10.8 ng/μmol Cr (cf. 7.1± 0.5 in healthy controls)
Ikuma et al. [18]311.0 (155.8-633.5) μg/g Cr in LN patient group (cf. 127.0 (69.3–177.0) in lupus patients without nephritis)
Zhu et al. [20]5.9-fold increase in uPODXL/uAQP2 concentration relative to healthy controls
IgA nephropathy (IgAN)Hara et al. [19]14.4 ± 10 ng/μmol Cr (cf. 7.1± 0.5 in healthy controls)
Asao et al. [22]82 μg/g Cr in patients with IgAN and FSGS with poor prognosis (cf. 50 for patients with good prognosis)
IgM nephropathy (IgMN)Zhu et al. [20]9.8-fold increase in uPODXL/uAQP2 concentration relative to healthy controls
ObesitySuwanpen et al. [23]A higher number of PODXL-positive cells in urine correlates with higher BMI (r = 0.343, p = 0.008)
  • BMI, body mass index; cf., compare to; Cr, creatinine; uAQP2, urinary aquaporin-2; uPODXL, urinary podocalyxin.